SecBot SecBot

IAM

Iambic Therapeutics, Inc.
Nasdaq· CIK 0001997038 Biotech & Drug Discovery
$14.79 +0.53 (+3.72%)
Oct 26 4:00 PM ET · prev $14.26
Market cap
$695.4M
Small cap
Since first trade
−21.8%
from $18.91 · Oct 15
30 days
−21.8%
from $18.91
Range since listing
$14.26–23.81
−38% from high · low Oct 23
Avg volume 8D
1.25M
shares / day
Insider net
+$11.5M
1 buyer · 0 sellers · 12 mo
Filing reports
11
analyzed by SecBot
SecBot read BULLISH 11 reports · 90 days
Balance 0 bearish · 2 bullish · 9 neutral oldest → newest, height = score
Avg score ·High conf. 11/11
Strongest BULLISH Iambic Therapeutics' IPO registration (S-1, File No. 333-299057) was declared effective by the SEC on…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $11.5M at an average $16.00. No open-market sales. Price is 8% below their cost.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 SEC
Director Evan Lockwood Rachlin made a single open-market purchase of 718,800 shares of Iambic Therapeutics at…
INSIDER-BUY — Impact 6/10
Oct 16, 2026 SEC
Iambic Therapeutics filed an 8-K on October 16, 2026, reporting the adoption of amended and restated certificate of…
8-K — Impact 2/10
Oct 16, 2026 Insider
Rachlin Evan Lockwood acquired 1,458,736 shares
Director
Oct 16, 2026 Insider
Rachlin Evan Lockwood acquired 410,762 shares
Director
Oct 16, 2026 Insider
Rachlin Evan Lockwood acquired 57,754 shares
Director
Oct 15, 2026 SEC
Iambic Therapeutics priced its IPO at $16.00 per share, offering 9,375,000 shares for total gross proceeds of $150.0…
424B4 — Impact 6/10
Oct 15, 2026 Trading halt
Halt Resumed: IAM — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-15T16:12:52.000Z | Resumed 2026-10-15T16:17:52.000Z

Insider ledger

Form 4
$11.5M
bought · 1 insider
$0
sold · 0 insiders
−7.6%
vs their $16.00 cost
DateInsiderTypeValue
Oct 16, 2026
Rachlin Evan Lockwood
Director
CONVERT1,458,736 sh
Oct 16, 2026
Rachlin Evan Lockwood
Director
CONVERT410,762 sh
Oct 16, 2026
Rachlin Evan Lockwood
Director
CONVERT57,754 sh
Oct 16, 2026
Rachlin Evan Lockwood
Director
CONVERT57,754 sh
Oct 16, 2026
Rachlin Evan Lockwood
Director
BUY$11.5M
Oct 16, 2026
Rachlin Evan Lockwood
Director
CONVERT1,152,025 sh
Oct 16, 2026
Rachlin Evan Lockwood
Director
CONVERT306,711 sh
Oct 16, 2026
Rachlin Evan Lockwood
Director
CONVERT410,762 sh

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA
Trading halts
Oct 15, 2026Volatility PauseResumed
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 15, 2026
Trading halt
Halt Resumed: IAM — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-15T16:12:52.000Z | Resumed 2026-10-15T16:17:52.000Z
Oct 15, 2026
Trading halt
Trading Halt: IAM — LUDP (Volatility Trading Pause)
Iambic Therapeutics Cmn Stk | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Oct 15, 2026
Listing
New Listing: IAM — Iambic Therapeutics, Inc. - Common Stock
Listed on exchange Q

SecBot reports

11 filings · 2 bullish · 0 bearish · 9 neutral
All IAM filing & press-release reports (11)